Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Preferred Stock Liabilities: 2017-2022

  • Dianthus Therapeutics' Preferred Stock Liabilities was N/A to $118.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $118.0 million, marking a year-over-year change of. This contributed to the annual value of $118.0 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q4 2022, Dianthus Therapeutics' Preferred Stock Liabilities is $118.0 million, which was up 27.68% from $92.4 million recorded in Q4 2017.
  • Over the past 5 years, Dianthus Therapeutics' Preferred Stock Liabilities peaked at $118.0 million during Q4 2022, and registered a low of $118.0 million during Q4 2022.
  • Over the past 1 years, Dianthus Therapeutics' median Preferred Stock Liabilities value was $118.0 million (recorded in 2022), while the average stood at $118.0 million.